Canterbury, United Kingdom
Canterbury, United Kingdom

Time filter

Source Type

Mowbray C.E.,Drugs for Neglected Diseases Initiative DNDi | Braillard S.,Drugs for Neglected Diseases Initiative DNDi | Speed W.,Drugs for Neglected Diseases Initiative DNDi | Glossop P.A.,Sandexis Medicinal Chemistry Ltd. | And 11 more authors.
Journal of Medicinal Chemistry | Year: 2015

Visceral leishmaniasis is a severe parasitic disease that is one of the most neglected tropical diseases. Treatment options are limited, and there is an urgent need for new therapeutic agents. Following an HTS campaign and hit optimization, a novel series of amino-pyrazole ureas has been identified with potent in vitro antileishmanial activity. Furthermore, compound 26 shows high levels of in vivo efficacy (>90%) against Leishmania infantum, thus demonstrating proof of concept for this series. © 2015 American Chemical Society.


PubMed | Pfizer, University of Antwerp, Drugs for Neglected Diseases initiative DNDi, AMG Consultants Ltd. and 3 more.
Type: Journal Article | Journal: Journal of medicinal chemistry | Year: 2015

Visceral leishmaniasis is a severe parasitic disease that is one of the most neglected tropical diseases. Treatment options are limited, and there is an urgent need for new therapeutic agents. Following an HTS campaign and hit optimization, a novel series of amino-pyrazole ureas has been identified with potent in vitro antileishmanial activity. Furthermore, compound 26 shows high levels of in vivo efficacy (>90%) against Leishmania infantum, thus demonstrating proof of concept for this series.


Bell A.S.,Pfizer | Bell A.S.,Imperial College London | Bradley J.,Pfizer | Bradley J.,Scitegrity Ltd | And 12 more authors.
Molecular Diversity | Year: 2016

High-throughput screening (HTS) is an effective method for lead and probe discovery that is widely used in industry and academia to identify novel chemical matter and to initiate the drug discovery process. However, HTS can be time consuming and costly and the use of subsets as an efficient alternative to screening entire compound collections has been investigated. Subsets may be selected on the basis of chemical diversity, molecular properties, biological activity diversity or biological target focus. Previously, we described a novel form of subset screening: plate-based diversity subset (PBDS) screening, in which the screening subset is constructed by plate selection (rather than individual compound cherry-picking), using algorithms that select for compound quality and chemical diversity on a plate basis. In this paper, we describe a second-generation approach to the construction of an updated subset: PBDS2, using both plate and individual compound selection, that has an improved coverage of the chemical space of the screening file, whilst only selecting the same number of plates for screening. We describe the validation of PBDS2 and its successful use in hit and lead discovery. PBDS2 screening became the default mode of singleton (one compound per well) HTS for lead discovery in Pfizer. © 2016 The Author(s)


PubMed | Imperial College London, Sandexis Medicinal Chemistry Ltd. and MISSION Therapeutics
Type: | Journal: ACS chemical biology | Year: 2016

Deubiquitinating enzymes play an important role in a plethora of therapeutically relevant processes and are emerging as pioneering drug targets. Herein, we present a novel probe, Ubiquitin Specific Protease (USP) inhibitor, alongside an alkyne-tagged activity-based probe analogue. Activity-based proteome profiling identified 12 USPs, including USP4, USP16, and USP33, as inhibitor targets using submicromolar probe concentrations. This represents the first intact cell activity-based profiling of deubiquitinating enzymes. Further analysis demonstrated functional inhibition of USP33 and identified a synergistic relationship in combination with ATR inhibition, consistent with USP4 inhibition.

Loading Sandexis Medicinal Chemistry Ltd collaborators
Loading Sandexis Medicinal Chemistry Ltd collaborators